Varian Medical Systems — Q3 FY2019 Earnings Presentation
33 slides from Varian Medical Systems's earnings presentation, Jul 24, 2019
Slide 1: Third Quarter Fiscal Year 2019
Third Quarter Fiscal Year 2019 July 24, 2019 J. Michael Bruff Senior Vice President, Investor Relations [email protected]
Slide 2: Forward-Looking Statements
This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. S
Slide 3: Agenda Q3 FY 2019 earnings
Agenda Q3 FY 2019 earnings 1. Third Quarter Results 2. Total Company Performance 3. Segment Performance 4. FY 2019 Guidance 5. Appendix VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY
Slide 4: Q3 FY 2019 key financial metrics
Q3 FY 2019 key financial metrics $M Q3 Y/Y Oncology Orders1 $778 2% • Delivered exceptional performance growing Non-GAAP operating earnings faster than Revenues $826 16% revenue Oncology $793 19% Proton Solutions $31 (26%) • US/China tariffs negatively impacted revenue growth by $10 million or 140 b
Slide 5: Long-term growth and value creation strategy
Long-term growth and value creation strategy Global Leader Global Leader in Multi-Disciplinary, in Radiation Therapy Integrated Cancer Care Solutions Interventional Surgical oncology oncology Radiation Radiosurgery oncology OIS Call on all Aggregate oncologists data Radiation oncology Radiation Radi
Slide 6: How we plan to achieve our strategy
How we plan to achieve our strategy We Are Here Long-Term Growth and Where We Are Headed Global Leader in Value Creation Strategy Global Leader in Multi- Radiation Therapy Disciplinary, Integrated Cancer Care Solutions Growth Priorities Interventional Surgical oncology oncology Radiation Radiosurger
Slide 7: Executing on long-term growth strategy
Executing on long-term growth strategy Strengthen Leadership Extend Expand in Radiation Therapy Global Footprint Addressable Market KEY METRICS KEY METRICS KEY METRICS • Global market leader • 8th consecutive quarter of double-digit • Software revenues grew +24% with >55% share in radiation therapy;
Slide 8: Key wins
Key wins Americas EMEA APAC U.S. Government – National Cancer Care India – Tata Trusts Uzbekistan VA Medical Alliance 6 TrueBeam systems 2 linear accelerators and 2 4 Halcyons, 3 TrueBeams, 6 TrueBeam systems brachytherapy systems 1 SRS, and 2 Bravos China Australia 5 Halcyon systems 3 TrueBeam syst
Slide 9: Varian linac net installed base
Varian linac net installed base Installed base growth 8,412 Varian strengthened its global leadership in radiation therapy • Net installed base grew +5% or 366 units, driving future recurring software and services revenues +366 (+5%) • All three geographies grew respective installed base in the thir
Slide 10: Total Company Performance
Total Company Performance varian
Slide 11: Total company results (GAAP)
Total company results (GAAP) Key P&L financial metrics • Gross Orders grew double digits due to three new proton orders taken in the quarter totalling $108 VARIAN million $M Q3 FY19 Y/Y TTM Y/Y • Revenue growth driven by strong hardware and Gross Orders $892 16% $3,457 11% software performance in th
Slide 12: Total company results (non-GAAP)
Total company results (non-GAAP) Key P&L financial metrics VARIAN • Gross Orders grew double digits due to three new proton orders taken in the quarter totalling $108 $M Q3 FY19 Y/Y TTM Y/Y million Gross Orders $892 16% $3,457 11% Revenues $826 16% $3,148 11% • Revenue growth driven by strong hardwa
Slide 13: Total company results: balance sheet and cash flow metrics
Total company results Key balance sheet and cash flow metrics Cash & Cash Equivalents ($M) Total Debt ($M) -2% Y/Y +383M Y/Y $700 $500 • Cash & Cash Equivalents of $523 million $400 • Total Debt of $401 million from borrowings $600 $300 related to the acquisition of CTSI, Endocare, and $200 Alicon $
Slide 14: Capital allocation priorities
Capital allocation priorities Q3 update Long-term value creation strategy that includes balancing growth, profitability and liquidity Organic • Investments in FLASH technology, software capability, key programs such as adaptive radiotherapy, and R&D and Capital infrastructure Investments Inorganic •
Slide 15: Segment Performance
Segment Performance varian
Slide 16: Oncology Systems segment (GAAP)
Oncology Systems segment (GAAP) Key financial metrics VARIAN • Gross Orders up +2% or +4% in constant $M Q3 FY19 Y/Y TTM Y/Y currency, and +11% over the trailing twelve Gross Orders $778 2% $3,328 11% months, or +13% in constant currency Revenues $793 19% $2,998 12% • Product Revenue growth driven b
Slide 17: Oncology Systems gross orders by geography
Oncology Systems gross orders by geography APAC AMERICAS -1% Q3 Y/Y -1% Q3 Y/Y1 (+1% cc) (-1% cc) 22% TTM Y/Y 6% TTM Y/Y1 (+24% cc) (+6% cc) (1) In North America, Q3 orders growth of -1% and TTM orders growth of 6% EMEA 8% Q3 Y/Y (+13% cc) 13% TTM Y/Y 17 (+17% cc)
Slide 18: Proton Solutions segment (GAAP)
Proton Solutions segment (GAAP) Key financial metrics • Gross Orders increased due to three new orders taken in the quarter totalling $108 million VARIAN • Product Revenues driven by the progress made in $M Q3 FY19 Y/Y TTM Y/Y centers under construction Gross Orders $111 2,866% $127 1% • Services Re
Slide 19: ProBeam proton therapy system sites
ProBeam proton therapy system sites 26 79 ProBeam Total Sites Rooms 11 35 Operational Operational Operational Centers Centers Under Development Sites Rooms1 (1) Number of Operational Rooms may not sum up to the total number on the map due to some sites having rooms which are under development. 19
Slide 20: FY 2019 Guidance
FY 2019 Guidance varian
Slide 21: Updated guidance for fiscal year 2019
Varian consolidated Updated guidance for fiscal year 2019 • Guidance considers projected market growth and continued momentum of Varian’s portfolio • Updated guidance considers the following impacts VARIAN to operating earnings: $M Prior Guidance Updated Guidance1 − $5 million positive impact due to
Slide 22: In summary, we are…
In summary, we are… Growing our net installed base Extending our global footprint and market-leading, best-in-class …Driving product portfolio toward our vision Becoming a global leader in multi-disciplinary, integrated cancer care solutions of a world without fear of cancer Delivering on our long-t
Slide 23: Appendix
Appendix
Slide 24: Non-GAAP disclosure
Non-GAAP disclosure Discussion of Non-GAAP Financial Measures This presentation includes the following non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings: non-GAAP operating earnings, non-GAAP net earnings and non-GAAP net earnings per diluted share. We define
Slide 25: GAAP to non-GAAP reconciliation
GAAP to non-GAAP reconciliation THE FOLLOWING TABLE RECONCILES GAAP AND NON-GAAP FINANCIAL MEASURES Dollars and shares in millions, except per share amounts 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Non-GAAP adjustments Amortization of intangible assets and inventory step-up (1) $4.1 $4.8 $4.2 $6.1 $6
Slide 26: Total revenues by sales classification
Total revenues by sales classification $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Product revenues 365.0 445.5 400.2 430.5 461.3 Y/Y 14% 11% 9% 9% 26% Service revenues 344.1 356.1 340.8 348.9 364.5 Y/Y 10% 11% 9% 4% 6% Total revenues 709.1 801.6 741.0 779.4 825.8 Y/Y 12% 11% 9% 7% 16% Y/Y – CC 10% 1
Slide 27: Total revenues by product type
Total revenues by product type $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 3Q Y/Y Hardware $314.6 $389.9 $347.2 $367.0 $387.9 23% Oncology Systems $276.5 $350.3 $313.6 $339.1 $361.7 31% Proton Solutions $38.1 $39.6 $33.6 $27.9 $24.2 -36% Other $2.0 —% Software1 $125.1 $132.3 $131.2 $144.2 $155.7 24%
Slide 28: Total revenues by region
Total revenues by region $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Americas revenues $342.6 $397.4 $350.4 $371.3 $401.2 Y/Y 2% 8% -2% 9% 17% Y/Y – CC 2% 8% -2% 10% 17% EMEA revenues $229.7 $266.3 $251.0 $261.5 $271.3 Y/Y 35% 21% 30% 3% 18% Y/Y – CC 28% 22% 33% 10% 24% APAC revenues $136.8 $137.9 $1
Slide 29: Total Oncology Systems revenues by sales classification
Total Oncology Systems revenues by sales classification $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Product revenues $326.9 $402.1 $366.6 $402.6 $433.8 Y/Y 29% 15% 8% 11% 33% Y/Y – CC 26% 15% 9% 14% 36% Service revenues $340.3 $353.5 $335.9 $344.2 $359.1 Y/Y 10% 11% 8% 3% 6% Y/Y – CC 7% 12% 9% 6% 8%
Slide 30: Total Oncology Systems revenues by region
Total Oncology Systems revenues by region $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Americas revenues $323.2 $369.5 $330.8 $357.1 $385.6 Y/Y 13% 6% -2% 11% 19% Y/Y – CC 13% 7% -2% 12% 20% EMEA revenues $208.5 $250.0 $234.5 $245.3 $256.4 Y/Y 32% 27% 28% 2% 23% Y/Y – CC 24% 28% 31% 9% 30% APAC revenu
Slide 31: Total Proton Solutions revenues by sales classification
Total Proton Solutions revenues by sales classification $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Product revenues $38.1 $43.4 $33.6 $27.9 $25.5 Y/Y -43% -12% 23% -7% -33% Service revenues $3.8 $2.6 $4.9 $4.7 $5.4 Y/Y 95% -23% 172% 151% 44% Total revenues $41.9 $46.0 $38.5 $32.6 $30.9 Y/Y -39% -12%
Slide 32: Oncology Systems gross orders by region
Oncology Systems gross orders by region $M 3Q FY18 4Q FY18 1Q FY19 2Q FY19 3Q FY19 Americas orders $362.9 $505.7 $335.9 $366.1 $357.4 Y/Y 9% 6% 12% 7% -1% Y/Y – CC 9% 6% 12% 8% -1% EMEA orders $259.1 $360.8 $218.3 $233.3 $281.1 Y/Y 27% 14% 15% 17% 8% Y/Y – CC 21% 15% 17% 25% 13% APAC orders $141.3 $
Slide 33: Our promise: People powering victories
Our promise People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer. W
Varian Medical Systems — Q3 FY2019 Earnings Presentation on 6ix